Oestrogen Receptors in Primary and Advanced Breast Cancer: an Eight Year Review of 704 Cases

Overview

Journal Br J Cancer

Specialty Oncology

Date 1987 Jan 1

PMID 3814477

Citations 19

Authors

M R Williams

J H Todd

I O Ellis

C S Dowle

J L Haybittle

C W Elston

R I Nicholson

K Griffiths

R W Blamey

Affiliations

Soon will be listed here.

Abstract

ER content of primary tumour tissue has been examined in 704 patients presenting with operable breast cancer. The median follow-up is now 84 months and no patient has received adjuvant therapy of any kind. ER status is related to histological grade, menopausal status, initial site of metastases and subsequent response to endocrine therapy. A significant advantage in terms of survival is found in ER positive patients which is confined to those lymph node positive at mastectomy. DFI is also significantly related to ER status in lymph node positive patients. Survival after the symptomatic presentation of metastases and the institution of endocrine therapy is prolonged in patients with ER positive tumours. The overall response rate to endocrine therapy in assessable patients with ER positive tumours is 32%. By combining the ER status and histological grade of tumour tissue, a group of patients comprising 28% of those assessable to endocrine therapy can be identified (ER positive, grade I and II) with a response rate of 46%.

Citing Articles

Comparison of the clinicopathological characteristics and prognosis between Chinese patients with breast cancer with bone-only and non-bone-only metastasis.

Zhang L, Zhang J, Li Z, Wu Y, Tong Z Oncol Lett. 2020; 20(4):92.

PMID: 32831911 PMC: 7439125. DOI: 10.3892/ol.2020.11953.

Analysis of clinicopathological factors associated with bone metastasis in breast cancer.

Chen J, Zhu S, Xie X, Guo S, Tong L, Zhou S J Huazhong Univ Sci Technolog Med Sci. 2013; 33(1):122-125.

PMID: 23392720 DOI: 10.1007/s11596-013-1083-1.

The prolyl isomerase Pin1 acts synergistically with CDK2 to regulate the basal activity of estrogen receptor α in breast cancer.

Lucchetti C, Caligiuri I, Toffoli G, Giordano A, Rizzolio F PLoS One. 2013; 8(2):e55355.

PMID: 23390529 PMC: 3563590. DOI: 10.1371/journal.pone.0055355.

Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?.

Lakhani S, Khanna K, Chenevix-Trench G Breast Cancer Res. 2010; 12(2):104.

PMID: 20346095 PMC: 2879558. DOI: 10.1186/bcr2483.

"Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer.

Agrawal A, Robertson J, Cheung K World J Surg Oncol. 2006; 4:40.

PMID: 16822312 PMC: 1538598. DOI: 10.1186/1477-7819-4-40.

References

HAYWARD J, Carbone P, HEUSON J, KUMAOKA S, SEGALOFF A, Rubens R . Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977; 39(3):1289-94. DOI: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f. View

Masters J, Millis R, Rubens R . Response to endocrine therapy and breast cancer differentiation. Breast Cancer Res Treat. 1986; 7(1):31-4. DOI: 10.1007/BF01886733. View

Maynard P, Blamey R, Elston C, Haybittle J, Griffiths K . Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res. 1978; 38(11 Pt 2):4292-5. View

Roberts M, Rubens R, King R, Hawkins R, Millis R, HAYWARD J . Oestrogen receptors and the response to endocrine therapy in advanced breast cancer. Br J Cancer. 1978; 38(3):431-6. PMC: 2009752. DOI: 10.1038/bjc.1978.225. View

Maynard P, Davies C, Blamey R, Elston C, Johnson J, Griffiths K . Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. Br J Cancer. 1978; 38(6):745-8. PMC: 2009828. DOI: 10.1038/bjc.1978.282. View

Cooke T, George D, Shields R, Maynard P, Griffiths K . Oestrogen receptors and prognosis in early breast cancer. Lancet. 1979; 1(8124):995-7. DOI: 10.1016/s0140-6736(79)92752-1. View

Bishop H, Blamey R, Elston C, Haybittle J, Nicholson R, Griffiths K . Relationship of oestrogen-receptor status to survival in breast cancer. Lancet. 1979; 2(8137):283-4. DOI: 10.1016/s0140-6736(79)90295-2. View

Allegra J, Lippman M, Simon R, Thompson E, Barlock A, Green L . Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep. 1979; 63(8):1271-7. View

HILF R, Feldstein M, Gibson S, SAVLOV E . The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer. 1980; 45(8):1993-2000. DOI: 10.1002/1097-0142(19800415)45:8<1993::aid-cncr2820450802>3.0.co;2-2. View

10.

Allegra J, Lippman M, Thompson E, Simon R, Barlock A, Green L . Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer. Eur J Cancer (1965). 1980; 16(3):323-31. DOI: 10.1016/0014-2964(80)90348-5. View

11.

Blamey R, Bishop H, Blake J, DOYLE P, Elston C, Haybittle J . Relationship between primary breast tumor receptor status and patient survival. Cancer. 1980; 46(12 Suppl):2765-9. DOI: 10.1002/1097-0142(19801215)46:12+<2765::aid-cncr2820461404>3.0.co;2-c. View

12.

Osborne C, Yochmowitz M, Knight 3rd W, McGuire W . The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980; 46(12 Suppl):2884-8. DOI: 10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u. View

13.

SAMAAN N, Buzdar A, Aldinger K, Schultz P, Yang K, Romsdahl M . Estrogen receptor: a prognostic factor in breast cancer. Cancer. 1981; 47(3):554-60. DOI: 10.1002/1097-0142(19810201)47:3<554::aid-cncr2820470322>3.0.co;2-w. View

14.

Millis R, Rubens R, Masters J, Minton M . Histological grade and response to endocrine therapy in breast cancer. Lancet. 1981; 2(8237):101. DOI: 10.1016/s0140-6736(81)90459-1. View

15.

Kinne D, Ashikari R, Butler A, Rosen P, Schwartz M . Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer. 1981; 47(10):2364-7. DOI: 10.1002/1097-0142(19810515)47:10<2364::aid-cncr2820471007>3.0.co;2-s. View

16.

Campbell F, Blamey R, Elston C, Nicholson R, Griffiths K, Haybittle J . Oestrogen-receptor status and sites of metastasis in breast cancer. Br J Cancer. 1981; 44(3):456-9. PMC: 2010785. DOI: 10.1038/bjc.1981.205. View

17.

Nicholson R, Campbell F, Blamey R, Elston C, George D, Griffiths K . Steroid receptors in early breast cancer: value in prognosis. J Steroid Biochem. 1981; 15:193-9. DOI: 10.1016/0022-4731(81)90275-2. View

18.

Haybittle J, Blamey R, Elston C, Johnson J, DOYLE P, Campbell F . A prognostic index in primary breast cancer. Br J Cancer. 1982; 45(3):361-6. PMC: 2010939. DOI: 10.1038/bjc.1982.62. View

19.

Neifeld J, LAWRENCE Jr W, Brown P, Banks W, TERZ J . Estrogen receptors in primary breast cancer. Arch Surg. 1982; 117(6):753-7. DOI: 10.1001/archsurg.1982.01380300001001. View

20.

Paterson A, Zuck V, Szafran O, Lees A, Hanson J . Influence and significance of certain prognostic factors on survival in breast cancer. Eur J Cancer Clin Oncol. 1982; 18(10):937-43. DOI: 10.1016/0277-5379(82)90241-3. View